Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1291-1296

  Syed, Misha F ^a   Loucks, Emma K R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Brinzolamide; Fixed combination therapy; Glaucoma; Ocular hypertension; Timolol

Indexed keywords

BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; POLYMER; PRESERVATIVE; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

ALLERGIC REACTION; BITTER TASTE; BLOOD PRESSURE; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CHEMOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA DISEASE; DEPRESSION; DERMATITIS; DIZZINESS; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRY EYE; DYSPNEA; EPIPHORA; EXERCISE TOLERANCE; EYE BURNING; EYE DISCHARGE; EYE DISCOMFORT; EYE IRRITATION; EYE PAIN; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HUMAN; HYDROGEL; HYPEREMIA; IMPOTENCE; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; KERATITIS; LACRIMAL FLUID LEVEL; LIBIDO DISORDER; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NONHUMAN; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PHOTOPHOBIA; PRURITUS; PUNCTATE KERATITIS; REVIEW; SIDE EFFECT; SORE THROAT; SYNCOPE; TASTE DISORDER; THORAX PAIN; TREATMENT RESPONSE; URTICARIA; XEROSTOMIA;

EID: 81055125661     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s13786     Document Type: Review

References (34)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.
2. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30-S36.
3. Rhee DJ, Rapuano CJ, Papaliodis GN, Fraunfelder FW, editors. Physicians' Desk Reference for Ophthalmic Medicines. 39th ed. Montvale, NJ: PDR Network, LLC; 2010.
4. Allingham RR, Damji KF, Freedman S, Moroi SE, Shafranov G, Shields MB, editors. Shields' Textbook of Glaucoma. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005.
5. White CJ, Byrne ME. Molecularly imprinted therapeutic contact lenses. Expert Opin Drug Deliv. 2010;7(6):765-780.
6. Singh V, Bushetti SS, Appala R, Shareef A, Imam SS, Singh M. Stimuli-sensitive hydrogels: A novel ophthalmic drug delivery system. Indian J Ophthalmol. 2010;58:477-481.
7. Hui-Hui A, Qiu-Hua L, Zhi-Jun Y, Wei-San P, Shu-Fang N. Novel ophthalmic timolol maleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Delivery. Epub 2011, May 1. Available from informahealthcare.com. Accessed August 15, 2011.
8. Xu J, Xinsong L, Fuqian S. In vitro and in vivo evaluation of ketotifen fumarate-loaded silicone hydrogel contact lenses for ocular drug delivery. Drug Deliv. 2011;18(2):150-158.
9. Tsai JC, Forbes M. Medical Management of Glaucoma. 3rd ed. Caddo, OK: Professional Communications Inc; 2009.
10. Shaarawy T, Sherwood MB, Hitchings RA, Crowston JG. Glaucoma: Medical Diagnosis and Therapy, Volume 1. Beijing, China: Elsevier Limited; 2009.
11. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol. 2000;129(2):136-143.
12. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126(3):400-408.
13. Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235-243.
14. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115(10): 1728-1734.
15. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293-300.
16. Hollo G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: A new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2009;10(12): 2015-2024.
17. Tsukamoto H, Noma H, Matsuyama S, Ikeda H, Mishima HK. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther. 2005;21(2):170-173.
18. Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma. November 2, 2010. [Epub ahead of print].
19. Hollo G, Kothy P. Intraocular pressure reduction with travoprost/ timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin. 2008;24(6):1755-1761.
20. Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol. 2008;92(4):500-504.
21. Siesky B, Harris A, Brizendine E, et al. Literature review and metaanalysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol. 2009;54(1):33-46.
22. European Medicines Agency. European Public Assessment Report (EPAR): Azarga. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000960/WC500029824.pdf. Accessed January 19, 2011.
23. Kanner E, Tsai JC. Glaucoma medications: Use and safety in the elderly population. Drugs Aging. 2006;23(4):321-332.
24. Bartlett JD, editor. Ophthalmic Drug Facts. St Louis, MO: Facts and Comparisons; 2003.
25. Hollo G. Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension. Exp Rev Ophthalmol. 2009;4(2): 129-133.
26. Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: A literature review. Pharmacoeconomics. 2007;25(4): 287-308.
27. Juzych MS, Randhawa S, Shukairy A, Kaushal P, Gupta A, Shalauta N. Functional health literacy in patients with glaucoma in urban settings. Arch Ophthalmol. 2008;126(5):718-724.
28. Muir KW, Santiago-Turla C, Stinnett SS, et al. Health literacy and adherence to glaucoma therapy. Am J Ophthalmol. 2006;142(2): 223-226.
29. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204-1212.
30. Stewart WC, Day DG, Stewart JA, Holmes KT, Jenkins JN. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye (Lond). 2004;18(9):905-910.
31. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: Results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44 Suppl 2:S141-S145.
32. Mundorf TK, Rauchman SH, Williams RD, Notivol R. A patient preference comparison of Azarga (brinzolamide/timolol f ixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2(3):623-8.
33. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2008;24(6): 601-605.
34. Merck Sharp and Dohme Corporation. Available from: http://www.merck.com/product/usa/pi_circulars/c/cosopt/cosopt_pi.pdf. Accessed February 7, 2011.